First Long-Term Data on Atogepant for Migraine Prevention

Source link :

An interim analysis of an ongoing extension study supports the long-term safety and efficacy of the oral calcitonin gene-related peptide (CGRP) receptor antagonist atogepant (Qulipta) to prevent chronic and episodic migraine. The data show that 70% of patients treated with atogepant 60 mg daily achieved at least a 50% reduction in monthly migraine days at […]

Author : News Health

Publish date : 2024-04-16 15:16:03

Copyright for syndicated content belongs to the linked Source.